Granules India's revenues rise 37 percent
Hyderabad, April 24: Granules India Ltd., a fast growing pharmaceutical manufacturing company, has posted a growth of 37 percent in revenues for 2011-12.
The Hyderabad-based company registered revenues of Rs.653 crore against Rs.475 crore in the previous fiscal.
The net profit during the year was Rs.30 crore, a growth of 43 percent over 2010-11.
Krishna Prasad, Managing Director, Granules India, told reporters that the profit before tax was Rs.43 crore against Rs.27 crore during the previous financial year.
Giving a break-up of sales, he said Finished Dosage (FD) grew by 83 percent to Rs.185 crore, Pharmaceutical Formulation Intermediate (PFI) by 27 percent to Rs.197 crore and Active Pharmaceutical Ingredient (API) by 20 percent to Rs.181 crore.
The company is currently tripling FD capacity to 18 billion units and more than doubling PFI capacity to 18,000 tons. The expansions, taken up with an investment of Rs.60 crore, are scheduled to finish in June.
The company will start generating revenue from the new capacities in the second quarter of FY13, said Bhaskar Krishna, CEO, Granules India.
He said the company has strong order book to the tune of about Rs.400 crore. The firm expects 40 percent growth during 2012-13. Margins will also improve due to high utilization rates at all facilities, he added.